Selective MOSPD2-STARD3 interaction at ER contact sites governs late endosome/lysosome dynamics and cholesterol homeostasis

This study identifies the ER-resident protein MOSPD2 as a selective recruiter of the cholesterol transporter STARD3 at ER-late endosome/lysosome contact sites, establishing their specific interaction as a unique functional unit essential for maintaining lysosomal dynamics and cholesterol homeostasis.

The Gist

Imagine your cell as a bustling, high-tech city. Inside this city, there are different neighborhoods (organelles) that need to stay in touch to keep everything running smoothly. Two of the most important neighborhoods are the Endoplasmic Reticulum (ER), which acts like a massive central factory and warehouse, and the Late Endosomes/Lysosomes (LE/Lys), which act as the city's recycling and waste management centers.

For these two neighborhoods to exchange goods (like cholesterol, a vital building block for cell membranes), they don't need to merge into one big building. Instead, they form Membrane Contact Sites (MCSs). Think of these as "handshake zones" or "bridges" where the two membranes get very close (but don't touch) to pass items back and forth.

The Problem: The City's Recycling Centers are Overcrowded

In this study, scientists discovered a specific "bridge builder" protein called MOSPD2. Its job is to stand on the ER side of the handshake zone and grab a specific partner from the recycling center side to facilitate the exchange.

When the scientists removed MOSPD2 from the cell city, chaos ensued:

1. The Recycling Centers Exploded: The number of waste management centers (LE/Lys) doubled. They were everywhere, clogging up the streets.
2. Traffic Jam of Cholesterol: The recycling centers became clogged with cholesterol. It was like a delivery truck dropping off a massive pile of bricks but having no one to move them, so they just sat there, blocking the doors.
3. Stuck Vehicles: The recycling centers lost the ability to merge and recycle efficiently. They were stuck as small, isolated islands instead of forming a streamlined network.

The Solution: The Perfect Match (MOSPD2 and STARD3)

The scientists realized that MOSPD2 wasn't just a generic bridge builder. It had a very specific partner: a protein called STARD3, which acts like a specialized "cholesterol mover" inside the recycling center.

Here is the key discovery: MOSPD2 and STARD3 are a "power couple."

• The "Dating" Analogy: There are three similar proteins on the ER side (MOSPD2, VAP-A, and VAP-B) that could theoretically talk to STARD3. It's like having three potential suitors. However, STARD3 only really wants to date MOSPD2.
• The "Lock and Key" Analogy: The scientists found that MOSPD2 fits STARD3's "lock" perfectly and tightly. The other two suitors (VAP-A and VAP-B) are like keys that are slightly the wrong shape; they might wiggle into the lock, but they can't turn it to open the door.
• The Result: Because MOSPD2 is the only one who can really "hold hands" with STARD3 effectively, it is the only one who can keep the recycling centers organized and the cholesterol moving. If you take away MOSPD2, STARD3 is left alone, the bridge collapses, and the city falls into disarray.

Why Can't the Other Proteins Help?

You might ask, "If VAP-A and VAP-B are similar, why can't they just step in and do MOSPD2's job?"

The study shows that in the real world of the cell, quantity doesn't always beat quality. Even though VAP-A and VAP-B are much more common in the cell (like having a million people in the crowd), they are just too weakly connected to STARD3 to do the job. It's like having a million people trying to push a heavy door that only opens with a specific key. Unless you have that specific key (MOSPD2), the door stays shut.

However, the scientists found a workaround: If they forced the cell to make massive amounts of STARD3 (overexpression), the sheer number of STARD3 molecules eventually overwhelmed the system, forcing them to grab onto VAP-A or VAP-B just to get the job done. This proved that the problem wasn't that VAP-A/VAP-B couldn't work, but that under normal conditions, they are just too weak to compete with the strong bond between MOSPD2 and STARD3.

The Big Picture

This paper teaches us that cells aren't just random collections of parts. They are highly organized systems where specificity matters.

• Selectivity is Key: Just because two proteins can interact doesn't mean they should. The cell uses specific pairings (like MOSPD2 and STARD3) to create specialized zones with unique jobs.
• The "Handshake" Defines the Function: The specific way these proteins hold hands determines whether the recycling center stays healthy or becomes a clogged, cholesterol-filled mess.

In short, MOSPD2 is the specialized foreman who knows exactly how to work with STARD3 to keep the cell's waste management and cholesterol supply running smoothly. Without this specific partnership, the whole system grinds to a halt.

Technical Summary

1. Problem Statement

Membrane contact sites (MCSs) are critical for non-vesicular lipid exchange and organelle homeostasis. The Endoplasmic Reticulum (ER) utilizes a family of MSP-domain proteins—VAP-A, VAP-B, and MOSPD2—as tethers to recruit partner proteins containing FFAT motifs from other organelles.

• The Knowledge Gap: While these three ER-resident proteins share structural similarities and many common binding partners, their functional redundancy is unclear. Proteomics suggests they have hundreds of shared partners, yet genetic evidence shows distinct phenotypes (e.g., VAP-A knockout is lethal, while VAP-B and MOSPD2 knockouts are viable).
• Specific Question: How do cells achieve functional specificity among these MSP-domain tethers? Specifically, how do they regulate the homeostasis of Late Endosomes/Lysosomes (LE/Lys) and cholesterol trafficking, given that LE/Lys are major hubs for cholesterol metabolism?

2. Methodology

The authors employed a multidisciplinary approach combining cell biology, biochemistry, and quantitative imaging:

• Genetic Manipulation: Generation of CRISPR/Cas9 knockout (KO) cell lines for MOSPD2 and STARD3 in HeLa cells. Use of siRNA/shRNA for transient silencing of VAP-A, VAP-B, MOSPD2, STARD3, OSBP, and ORP1L.
• Rescue Experiments: Re-expression of Wild-Type (WT) and mutant constructs (domain deletions and point mutations) in KO cells to determine functional domains (e.g., MSP domain, CRAL-TRIO domain, FFAT motif phosphorylation sites).
• Imaging & Quantification:
  • Immunofluorescence & Live-cell imaging: Using markers like LAMP1, Lysotracker, EEA1, and cholesterol probes (Filipin, GFP-D4, mEGFP-D4H).
  • Super-resolution/Confocal Microscopy: To assess organelle number, size, spatial distribution (perinuclear vs. peripheral), and fusion dynamics.
  • Transmission Electron Microscopy (TEM): To visualize ultrastructural changes in LE/Lys.
  • FRAP (Fluorescence Recovery After Photobleaching): To measure the stability of protein interactions at ER-LE/Lys contacts.
• Biochemical Assays:
  • Co-immunoprecipitation (Co-IP): To assess protein-protein interactions.
  • Native Holdup Assay: A quantitative method using immobilized recombinant MSP domains to measure binding affinities ($K_d$) and maximal binding capacity ($B_{max}$) of endogenous partners in cell lysates.
• Functional Assays: Dual-color dextran pulse-chase assays to quantify endosomal fusion rates; fission assays using starvation-induced tubulation.

3. Key Contributions & Results

A. MOSPD2 is a Non-Redundant Regulator of LE/Lys Homeostasis

• Phenotype: Depletion of MOSPD2 (but not VAP-A or VAP-B) causes a ~2-fold expansion of the LE/Lys compartment (increased LAMP1+ vesicles) and a redistribution of these organelles from the perinuclear region to the cell periphery.
• Specificity: This phenotype is observed in both HeLa and MRC5 fibroblast cells, indicating a general mechanism.
• Mechanism: The MSP domain of MOSPD2 is essential for this function, while its CRAL-TRIO domain (involved in lipid droplet contact) is dispensable.

B. Cholesterol Accumulation and Fusion Defects

• Cholesterol: MOSPD2-deficient cells exhibit significant accumulation of free cholesterol within the LE/Lys membrane, visualized by Filipin and GFP-D4 probes.
• Fusion Dynamics: The expansion of LE/Lys is driven by impaired fusion, not increased fission. MOSPD2-deficient cells show reduced colocalization of sequential dextran pulses, indicating a block in endosomal maturation/fusion.
• Conclusion: MOSPD2 is required to maintain normal cholesterol levels and fusion competence of LE/Lys.

C. Identification of STARD3 as the Critical Partner

• Phenocopy: Silencing or knocking out STARD3 (a cholesterol transfer protein) recapitulates the MOSPD2 phenotype: LE/Lys expansion, peripheral redistribution, and cholesterol accumulation.
• Dependency: MOSPD2 cannot rescue the LE/Lys phenotype in STARD3-depleted cells, and vice versa. This confirms they function in the same pathway.
• Structure-Function: The cholesterol transport activity of STARD3 is essential. Mutants of STARD3 lacking the START domain (cholesterol binding) or the FFAT motif (MSP binding) fail to rescue the phenotype.

D. Selective Binding Hierarchy (The "Interaction Landscape")

• Preferential Binding: Despite VAP-A and VAP-B being more abundant, STARD3 preferentially binds to MOSPD2.
  • Co-IP: MOSPD2 co-precipitates more efficiently with STARD3 than VAP-A or VAP-B.
  • Holdup Assay: Quantitative binding assays revealed MOSPD2 binds STARD3 with significantly higher affinity ($K_d \approx 0.19 \mu M$) compared to VAP-A ($K_d \approx 0.62 \mu M$). Binding to VAP-B was negligible.
  • FRAP: GFP-MOSPD2 shows slower fluorescence recovery at STARD3-positive contacts compared to VAP-A/B, indicating a more stable complex.
• Competition & Abundance: Under physiological conditions, the high affinity of MOSPD2 for STARD3 allows it to capture the low-abundance STARD3 protein, outcompeting the more abundant but lower-affinity VAP-A/B.
• Overexpression Rescue: Overexpression of STARD3 can bypass the need for MOSPD2, forcing STARD3 to bind VAP-A/B and restore LE/Lys homeostasis. This proves that the limitation in WT cells is the availability of the high-affinity MOSPD2-STARD3 pair, not the inability of VAP-A/B to bind STARD3 at all.

E. Specificity of MSP-FFAT Interactions

• The study demonstrates that MSP-domain proteins are not generic tethers. They exhibit distinct binding preferences:
  • STARD3: Prefers MOSPD2 > VAP-A > VAP-B.
  • ORP1L: Binds strongly to MOSPD2.
  • OSBP: Prefers VAP-A and VAP-B over MOSPD2.
• This selectivity is dictated by the specific sequence of the MSP domain and the phosphorylation state of the FFAT motif.

4. Significance

• Redefining MCS Specificity: The paper challenges the view that MSP-domain proteins are functionally redundant. It establishes that binding affinity hierarchies and protein abundance create a specific "interaction landscape" that dictates organelle function.
• Mechanism of Cholesterol Homeostasis: It identifies a specific molecular unit (MOSPD2-STARD3) at ER-LE/Lys contacts that is essential for extracting cholesterol from lysosomes. Disruption leads to lysosomal cholesterol accumulation and fusion defects, which are hallmarks of lysosomal storage disorders.
• Therapeutic Implications: Understanding how specific tethering complexes regulate organelle dynamics provides new targets for diseases involving cholesterol trafficking (e.g., Niemann-Pick type C, atherosclerosis, and neurodegenerative diseases).
• General Principle: The findings suggest that cells organize MCSs not just by the presence of tethers, but by the selective pairing of high-affinity tether-partner complexes, ensuring that specific lipid exchange events occur at the correct location and time.

In summary, this work defines the MOSPD2-STARD3 complex as a unique, non-redundant functional unit that governs late endosome/lysosome dynamics and cholesterol homeostasis through a mechanism of selective, high-affinity tethering that cannot be compensated for by other abundant MSP-domain proteins under physiological conditions.